Oxford Vacmedix are a Biotech spin out from the University of Oxford Oncology department. They've developed an exciting new immunotherapy delivery system, utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Professor Shisong Jiang.

OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need:

• OVM-100 is an HPV vaccine targeted at cervical cancer
• OVM-200 represents a new type of vaccine utilising survivin to target solid tumours including prostate, ovarian and non-small cell lung cancer (NSCLC)

Initial dose escalation trials have demonstrated a strong immune response with very good safety results. They're looking to rasie Series B funding to advance Phase 2 and Phase 1 trials for OVM-200 and OVM-100 respectively.

At Proven connect we are excited about OVM's new technology and we look forward to providing further updates as to how they are transforming the treatment of prostate cancer.